<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Learn With Asif]]></title><description><![CDATA[Affordable Medical Learning Awaits You]]></description><link>https://www.learnwithasif.org/blog</link><generator>RSS for Node</generator><lastBuildDate>Wed, 03 Jun 2026 17:01:01 GMT</lastBuildDate><atom:link href="https://www.learnwithasif.org/blog-feed.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[Cardiovascular Risk in Chronic Inflammatory Biomarkers]]></title><description><![CDATA[Beyond the Joints It is a common misconception that diseases like Rheumatoid Arthritis and Psoriatic Arthritis are confined entirely to the musculoskeletal system. Accumulating epidemiological data indicates that systemic inflammation inherently drives accelerated atherogenesis, placing rheumatology patients at a significantly higher risk for cardiovascular disease (CVD) than the general public. The Pathophysiological Connection Chronic elevation of pro-inflammatory cytokines, specifically...]]></description><link>https://www.learnwithasif.org/post/cardiovascular-risk-in-chronic-inflammatory-biomarkers</link><guid isPermaLink="false">6a0856120b9e4f37fd275778</guid><pubDate>Sat, 16 May 2026 11:36:15 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/b2e4aa_af5ad043d460487b923db15d3c6610da~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>infolearnwithasif</dc:creator></item><item><title><![CDATA[The Evolving Diagnostic Landscape of Seronegative Rheumatoid Arthritis]]></title><description><![CDATA[Diagnosing Rheumatoid Arthritis (RA) typically relies heavily on serum biomarkers, specifically Rheumatoid Factor (RF) and Anti-Cyclic Citrullinated Peptide (anti-CCP) antibodies. However, approximately 20% to 30% of RA patients present with seronegative RA, meaning they display classic clinical symptoms of inflammatory arthritis but test negative for these traditional autoantibodies. In clinical practice, seronegative RA poses a significant diagnostic challenge, often leading to delays in...]]></description><link>https://www.learnwithasif.org/post/the-evolving-diagnostic-landscape-of-seronegative-rheumatoid-arthritis</link><guid isPermaLink="false">6a084f64df43effc8cdf428f</guid><pubDate>Sat, 16 May 2026 11:13:15 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/b2e4aa_b7d6af77efec408eaa2c6b82f32eebbd~mv2.jpeg/v1/fit/w_735,h_490,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>infolearnwithasif</dc:creator></item><item><title><![CDATA[Rheumatoid Arthritis and the “Window of Opportunity”]]></title><description><![CDATA[Why Early Treatment Changes Everything ? Rheumatoid Arthritis (RA) is not just joint pain, it is a systemic autoimmune disease that can cause irreversible joint damage if not treated early. Affects ~0.5% to 1% of the global population Women are affected 2–3 times more than men Peak onset: 30–50 years of age Up to 60% joint damage occurs in the first 2 years if untreated What is the “Window of Opportunity”? Modern rheumatology shows that the first 12 weeks after symptom onset is critical. This...]]></description><link>https://www.learnwithasif.org/post/rheumatoid-arthritis-and-the-window-of-opportunity</link><guid isPermaLink="false">6a045b12c789fae117572d29</guid><pubDate>Wed, 13 May 2026 11:18:03 GMT</pubDate><dc:creator>infolearnwithasif</dc:creator></item></channel></rss>